

Stefano Partelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1887192/publications.pdf>

Version: 2024-02-01

198
papers

8,056
citations

46918

47
h-index

62479

80
g-index

203
all docs

203
docs citations

203
times ranked

7285
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole-genome landscape of pancreatic neuroendocrine tumours. <i>Nature</i> , 2017, 543, 65-71.	13.7	716
2	Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. <i>Surgery</i> , 2011, 150, 75-82.	1.0	306
3	Mucin-Producing Neoplasms of the Pancreas: An Analysis of Distinguishing Clinical and Epidemiologic Characteristics. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 213-219.e4.	2.4	289
4	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2017, 105, 255-265.	1.2	231
5	Middle Pancreatectomy. <i>Annals of Surgery</i> , 2007, 246, 69-76.	2.1	222
6	Observational Study of Natural History of Small Sporadic Nonfunctioning Pancreatic Neuroendocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4784-4789.	1.8	212
7	Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis. <i>Cut</i> , 2017, 66, 495-506.	6.1	177
8	Pattern and Clinical Predictors of Lymph Node Involvement in Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNETs). <i>JAMA Surgery</i> , 2013, 148, 932.	2.2	154
9	Malignant pancreatic neuroendocrine tumour: Lymph node ratio and Ki67 are predictors of recurrence after curative resections. <i>European Journal of Cancer</i> , 2012, 48, 1608-1615.	1.3	149
10	Resectable Pancreatic Cancer: Who Really Benefits From Resection?. <i>Annals of Surgical Oncology</i> , 2009, 16, 3316-3322.	0.7	143
11	Systematic review of active surveillance <i>versus</i> surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. <i>British Journal of Surgery</i> , 2016, 104, 34-41.	0.1	140
12	Surgical Management of Insulinomas. <i>Archives of Surgery</i> , 2012, 147, 261.	2.3	126
13	Total pancreatectomy: Indications, different timing, and perioperative and long-term outcomes. <i>Surgery</i> , 2011, 149, 79-86.	1.0	109
14	Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1533-1539.	0.5	104
15	Delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy: validation of International Study Group of Pancreatic Surgery classification and analysis of risk factors. <i>Hpb</i> , 2010, 12, 610-618.	0.1	102
16	A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2018, 267, 1148-1154.	2.1	101
17	Prognosis of sporadic resected small ($\leq 2\text{ cm}$) nonfunctional pancreatic neuroendocrine tumors â€“ a multi-institutional study. <i>Hpb</i> , 2018, 20, 251-259.	0.1	99
18	Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. <i>Surgery</i> , 2014, 155, 145-153.	1.0	92

#	ARTICLE	IF	CITATIONS
19	Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. <i>American Journal of Surgery</i> , 2012, 203, 132-139.	0.9	86
20	Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer. <i>Digestive and Liver Disease</i> , 2012, 44, 945-951.	0.4	85
21	Partial Pancreaticoduodenectomy Can Provide Cure for Duodenal Gastrinoma Associated With Multiple Endocrine Neoplasia Type 1. <i>Annals of Surgery</i> , 2013, 257, 308-314.	2.1	84
22	Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67. <i>Annals of Surgical Oncology</i> , 2018, 25, 2467-2474.	0.7	82
23	Increased rate of clinically relevant pancreatic fistula after deep enucleation of small pancreatic tumors. <i>Langenbeck's Archives of Surgery</i> , 2014, 399, 315-321.	0.8	78
24	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. <i>Neuroendocrinology</i> , 2018, 107, 375-386.	1.2	78
25	Laparoscopic rectal resection for severe endometriosis of the mid and low rectum: technique and operative results. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 1035-1040.	1.3	76
26	A systematic review on robotic pancreaticoduodenectomy. <i>Surgical Oncology</i> , 2013, 22, 238-246.	0.8	76
27	Intraductal papillary mucinous neoplasms of the pancreas with multifocal involvement of branch ducts. <i>American Journal of Surgery</i> , 2009, 198, 709-714.	0.9	74
28	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2015, 22, 2094-2100.	0.7	72
29	Pancreatic Cystic Endocrine Tumors: A Different Morphological Entity Associated with a Less Aggressive Behavior. <i>Neuroendocrinology</i> , 2010, 92, 246-251.	1.2	71
30	Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases. <i>Neuroendocrinology</i> , 2015, 102, 68-76.	1.2	71
31	Invasive Intraductal Papillary Mucinous Carcinomas of the Pancreas. <i>Annals of Surgery</i> , 2010, 251, 477-482.	2.1	69
32	Parenchyma-sparing resections for pancreatic neoplasms. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010, 17, 782-787.	1.4	67
33	Systematic review and meta-analysis of metal versus plastic stents for preoperative biliary drainage in resectable periampullary or pancreatic head tumors. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1278-1285.	0.5	67
34	Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. <i>British Journal of Surgery</i> , 2012, 99, 1234-1240.	0.1	65
35	Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters. <i>Surgery</i> , 2016, 159, 862-871.	1.0	65
36	Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. <i>Surgery</i> , 2018, 163, 761-767.	1.0	65

#	ARTICLE	IF	CITATIONS
37	Management of ampullary neoplasms: A tailored approach between endoscopy and surgery. <i>World Journal of Gastroenterology</i> , 2015, 21, 7970.	1.4	59
38	Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1&G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 981-989.	0.7	58
39	A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2019, 270, 422-433.	2.1	53
40	Early Postoperative Prediction of Clinically Relevant Pancreatic Fistula after Pancreaticoduodenectomy: usefulness of C-reactive Protein. <i>Hpb</i> , 2017, 19, 580-586.	0.1	52
41	Current status of robotic distal pancreatectomy: A systematic review. <i>Surgical Oncology</i> , 2013, 22, 201-207.	0.8	51
42	The Role of Combined 68Ga-DOTANOC and 18FDG PET/CT in the Management of Patients with Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2014, 100, 293-299.	1.2	51
43	Risk of misdiagnosis and overtreatment in patients with main pancreatic duct dilatation and suspected combined/main-duct intraductal papillary mucinous neoplasms. <i>Surgery</i> , 2016, 159, 1041-1049.	1.0	51
44	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1197-1205.	3.3	50
45	A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 102, 95-102.	1.3	50
46	Active Surveillance versus Surgery of Nonfunctioning Pancreatic Neuroendocrine Neoplasms >= 2 cm in MEN1 Patients. <i>Neuroendocrinology</i> , 2016, 103, 779-786.	1.2	49
47	Pancreaticojejunostomy is comparable to pancreaticogastrostomy after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials. <i>Langenbeck's Archives of Surgery</i> , 2016, 401, 427-437.	0.8	49
48	The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. <i>European Journal of Surgical Oncology</i> , 2018, 44, 778-783.	0.5	49
49	Enhanced recovery pathways in pancreatic surgery: State of the art. <i>World Journal of Gastroenterology</i> , 2016, 22, 6456.	1.4	49
50	Differences between main-duct and branch-duct intraductal papillary mucinous neoplasms of the pancreas. <i>World Journal of Gastrointestinal Surgery</i> , 2010, 2, 342.	0.8	47
51	Advanced Digestive Neuroendocrine Tumors. <i>Pancreas</i> , 2014, 43, 212-218.	0.5	46
52	Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation. <i>European Journal of Surgical Oncology</i> , 2017, 43, 372-379.	0.5	46
53	Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNEs): A systematic review. <i>Advances in Medical Sciences</i> , 2016, 61, 147-153.	0.9	45
54	Update on gastroenteropancreatic neuroendocrine tumors. <i>Digestive and Liver Disease</i> , 2021, 53, 171-182.	0.4	45

#	ARTICLE	IF	CITATIONS
55	Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. PLoS ONE, 2017, 12, e0179445.	1.1	45
56	Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?. Annals of Surgical Oncology, 2020, 27, 1348-1355.	0.7	44
57	Evaluation of an enhanced recovery protocol after pancreaticoduodenectomy in elderly patients. Hpb, 2016, 18, 153-158.	0.1	43
58	Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. Oncologist, 2017, 22, 409-415.	1.9	42
59	Evaluation of a predictive model for pancreatic fistula based on amylase value in drains after pancreatic resection. American Journal of Surgery, 2014, 208, 634-639.	0.9	41
60	Splenic Artery Invasion in Pancreatic Adenocarcinoma of the Body and Tail: A Novel Prognostic Parameter for Patient Selection. Annals of Surgical Oncology, 2011, 18, 3608-3614.	0.7	40
61	Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: Limitations to apply guidelines into real life. Surgery, 2019, 166, 157-163.	1.0	40
62	Long-Term Outcome after Laparoscopic Bowel Resections for Deep Infiltrating Endometriosis: A Single-Center Experience after 900 Cases. BioMed Research International, 2014, 2014, 1-5.	0.9	39
63	Clinical Usefulness of 18 Fâ€Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Enteroâ€Pancreatic Neuroendocrine Neoplasms. Oncologist, 2018, 23, 186-192.	1.9	39
64	The treatment of hyperinsulinemic hypoglycaemia in adults: an update. Journal of Endocrinological Investigation, 2017, 40, 9-20.	1.8	38
65	Extent of surgical resections for intraductal papillary mucinous neoplasms. World Journal of Gastrointestinal Surgery, 2010, 2, 347.	0.8	37
66	Perioperative and long-term results after left pancreatectomy: a single-institution, non-randomized, comparative study between open and laparoscopic approach. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 2871-2878.	1.3	36
67	Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology, 2016, 98, 309-324.	2.0	35
68	Implications of increased serum amylase after pancreaticoduodenectomy: toward a better definition of clinically relevant postoperative acute pancreatitis. Hpb, 2020, 22, 1645-1653.	0.1	33
69	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) â‰¥2 cm: Study Protocol for a Prospective Observational Study. Frontiers in Medicine, 2020, 7, 598438.	1.2	33
70	Surgical Treatment of Pancreatic Tumors in Childhood and Adolescence: Uncommon Neoplasms with Favorable Outcome. Pancreatology, 2011, 11, 383-389.	0.5	32
71	Systematic review and meta-analysis on laparoscopic pancreatic resections for neuroendocrine neoplasms (PNEs). Expert Review of Gastroenterology and Hepatology, 2017, 11, 65-73.	1.4	32
72	Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2021, 111, 273-287.	1.2	32

#	ARTICLE	IF	CITATIONS
73	Right hemicolectomy plus pancreaticoduodenectomy vs partial duodenectomy in treatment of locally advanced right colon cancer invading pancreas and/or only duodenum. <i>Surgical Oncology</i> , 2014, 23, 92-98.	0.8	31
74	Selection criteria in resectable pancreatic cancer: A biological and morphological approach. <i>World Journal of Gastroenterology</i> , 2014, 20, 11210.	1.4	31
75	Radiomics in pancreatic neuroendocrine tumors: methodological issues and clinical significance. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4002-4015.	3.3	31
76	GEPâ€“NETS UPDATE: A review on surgery of gastro-entero-pancreatic neuroendocrine tumors. <i>European Journal of Endocrinology</i> , 2014, 171, R153-R162.	1.9	30
77	Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology. <i>World Journal of Gastroenterology</i> , 2016, 22, 9944.	1.4	30
78	Portal Vein Embolization and Ligation for Extended Hepatectomy. <i>Indian Journal of Surgical Oncology</i> , 2014, 5, 30-42.	0.3	29
79	A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. <i>Hpb</i> , 2018, 20, 197-203.	0.1	29
80	Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Shortâ€“Term and Longâ€“Term Outcomes. <i>World Journal of Surgery</i> , 2018, 42, 3223-3230.	0.8	29
81	Poorly differentiated resectable pancreatic cancer: Is upfront resection worthwhile?. <i>Surgery</i> , 2012, 152, S112-S119.	1.0	28
82	mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2016, 23, 883-891.	1.6	28
83	Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. <i>Neuroendocrinology</i> , 2016, 103, 531-537.	1.2	28
84	A systematic review and meta-analysis of spleen-preserving distal pancreatectomy with preservation or ligation of the splenic artery and vein. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2016, 14, 109-118.	0.8	28
85	Multimodal treatment of resectable pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 152-165.	2.0	28
86	Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment. <i>Nuclear Medicine Communications</i> , 2020, 41, 896-905.	0.5	28
87	Middle-preserving pancreatectomy for multicentric body-sparing lesions of the pancreas. <i>American Journal of Surgery</i> , 2009, 198, e49-e53.	0.9	27
88	Plasticity of human dedifferentiated adipocytes toward endothelial cells. <i>Experimental Hematology</i> , 2015, 43, 137-146.	0.2	27
89	Surgical management of neuroendocrine tumors. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 93-102.	2.2	27
90	Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1486-1494.	1.8	27

#	ARTICLE	IF	CITATIONS
91	Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategyâ€”A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 264-274.	2.0	26
92	Is the Real Prevalence of Pancreatic Neuroendocrine Tumors Underestimated? A Retrospective Study on a Large Series of Pancreatic Specimens. <i>Neuroendocrinology</i> , 2019, 109, 165-170.	1.2	26
93	Risk and Predictors of Postoperative Morbidity and Mortality After Pancreaticoduodenectomy for Pancreatic Neuroendocrine Neoplasms. <i>Pancreas</i> , 2019, 48, 504-509.	0.5	26
94	DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2019, 9, 18614.	1.6	26
95	A systematic review and meta-analysis on the role of omental or falciform ligament wrapping during pancreaticoduodenectomy. <i>Hpb</i> , 2020, 22, 1227-1239.	0.1	26
96	Adequacy of Lymph Node Retrieval for Ampullary Cancer and Its Association with Improved Staging and Survival. <i>World Journal of Surgery</i> , 2013, 37, 1397-1404.	0.8	25
97	Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest). <i>Annals of Surgical Oncology</i> , 2021, 28, 7506-7517.	0.7	25
98	Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2018, 44, 24-30.	0.5	24
99	Preoperative risk stratification of postoperative pancreatic fistula: A risk-tree predictive model for pancreatoduodenectomy. <i>Surgery</i> , 2021, 170, 1596-1601.	1.0	21
100	Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas. <i>World Journal of Gastroenterology</i> , 2014, 20, 10008.	1.4	21
101	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. <i>JAMA Network Open</i> , 2022, 5, e220290.	2.8	21
102	Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms. <i>PLoS ONE</i> , 2018, 13, e0197035.	1.1	20
103	Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms. <i>Diagnostics</i> , 2021, 11, 192.	1.3	20
104	Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival. <i>Annals of Surgical Oncology</i> , 2021, 28, 8249-8260.	0.7	20
105	Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 389.	0.8	20
106	68Ga-DOTATOC PET/MR imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine well-differentiated tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2352-2363.	3.3	20
107	Single-incision laparoscopic cholecystectomy versus traditional laparoscopic cholecystectomy performed by a single surgeon: findings of a randomized trial. <i>Surgery Today</i> , 2016, 46, 313-318.	0.7	19
108	Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3. <i>American Journal of Surgery</i> , 2020, 220, 284-289.	0.9	19

#	ARTICLE	IF	CITATIONS
109	Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2020, 27, 3928-3936.	0.7	19
110	Impact of enhanced recovery protocols after pancreatoduodenectomy: meta-analysis. <i>British Journal of Surgery</i> , 2022, 109, 256-266.	0.1	19
111	Extent of Surgery and Implications of Transection Margin Status after Resection of IPMNs. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-10.	0.7	18
112	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. <i>Pancreatology</i> , 2018, 18, 198-203.	0.5	18
113	Combined ⁶⁸ Ga-DOTA-peptides and ¹⁸ F-FDG PET in the diagnostic work-up of neuroendocrine neoplasms (NEN). <i>Clinical and Translational Imaging</i> , 2019, 7, 181-188.	1.1	18
114	Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. <i>Translational Oncology</i> , 2019, 12, 1-7.	1.7	18
115	Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?. <i>Surgery</i> , 2021, 169, 403-410.	1.0	18
116	R Status is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 4602-4612.	0.7	18
117	A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. <i>Updates in Surgery</i> , 2020, 72, 39-45.	0.9	17
118	Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre. <i>Hpb</i> , 2013, 15, 958-964.	0.1	16
119	Evaluation of cost-effectiveness among open, laparoscopic and robotic distal pancreatectomy: A systematic review and meta-analysis. <i>American Journal of Surgery</i> , 2021, 222, 513-520.	0.9	16
120	The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age. <i>Digestive and Liver Disease</i> , 2019, 51, 735-740.	0.4	15
121	Outcomes after distal pancreatectomy for neuroendocrine neoplasms: a retrospective comparison between minimally invasive and open approach using propensity score weighting. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 165-173.	1.3	15
122	Sporadic non-functioning pancreatic neuroendocrine tumours: multicentre analysis. <i>British Journal of Surgery</i> , 2021, 108, 811-816.	0.1	15
123	Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology. <i>Hpb</i> , 2021, 23, 1666-1673.	0.1	15
124	The role of acinar content at pancreatic resection margin in the development of postoperative pancreatic fistula and acute pancreatitis after pancreaticoduodenectomy. <i>Surgery</i> , 2021, 170, 1215-1222.	1.0	15
125	Rectal Indomethacin to Prevent Post-ERCP Pancreatitis. <i>New England Journal of Medicine</i> , 2012, 367, 277-279.	13.9	14
126	The role of ¹⁸ fluoro-deoxyglucose positron emission tomography/computed tomography in resectable pancreatic cancer. <i>Digestive and Liver Disease</i> , 2014, 46, 744-749.	0.4	14

#	ARTICLE	IF	CITATIONS
127	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. <i>Surgical Oncology</i> , 2020, 35, 141-148.	0.8	14
128	Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1524-1531.	0.5	14
129	Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 705-718.	1.8	14
130	Evidence of a common cell origin in a case of pancreatic mixed intraductal papillary mucinous neoplasm and neuroendocrine tumor. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 1215-1219.	1.4	13
131	Preoperative predictive factors of laparoscopic distal pancreatectomy difficulty. <i>Hpb</i> , 2020, 22, 1766-1774.	0.1	13
132	Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT). <i>Endocrine Pathology</i> , 2020, 31, 119-131.	5.2	13
133	Prognostic Role of Examined and Positive Lymph Nodes after Distal Pancreatectomy for Non-Functioning Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2021, 111, 728-738.	1.2	13
134	Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms. <i>Current Treatment Options in Oncology</i> , 2020, 21, 48.	1.3	13
135	Management of rectosigmoid obstruction due to severe bowel endometriosis. <i>Updates in Surgery</i> , 2014, 66, 59-64.	0.9	12
136	Postoperative Outcomes and Functional Recovery After Preoperative Combination Chemotherapy for Pancreatic Cancer: A Propensity Score-Matched Study. <i>Frontiers in Oncology</i> , 2019, 9, 1299.	1.3	12
137	Portal vein resection during pancreaticoduodenectomy for pancreatic neuroendocrine tumors. An international multicenter comparative study. <i>Surgery</i> , 2021, 169, 1093-1101.	1.0	12
138	A tug-of-war in intraductal papillary mucinous neoplasms management: Comparison between 2017 International and 2018 European guidelines. <i>Digestive and Liver Disease</i> , 2021, 53, 998-1003.	0.4	12
139	Ezrin Expression Is an Independent Prognostic Factor in Gastro-intestinal Cancers. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 2082-2091.	0.9	11
140	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017, 6, 1493-1499.	1.3	11
141	Long-Term Pancreatic Functional Impairment after Surgery for Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2019, 8, 1611.	1.0	11
142	Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma. <i>BJS Open</i> , 2019, 3, 646-655.	0.7	11
143	Main Duct Thresholds for Malignancy Are Different in Intraductal Papillary Mucinous Neoplasms of the Pancreatic Head and Body-Tail. <i>Clinical Gastroenterology and Hepatology</i> , 2020, , .	2.4	11
144	Diagnostic accuracy of EUS-FNA in the evaluation of pancreatic neuroendocrine neoplasms grading: Possible clinical impact of misclassification. <i>Endoscopic Ultrasound</i> , 2021, 10, 372.	0.6	11

#	ARTICLE	IF	CITATIONS
145	SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer. <i>Digestive and Liver Disease</i> , 2018, 50, 84-90.	0.4	10
146	Local treatment for focal progression in metastatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2019, 26, 405-409.	1.6	10
147	Early biochemical predictors of clinically relevant pancreatic fistula after distal pancreatectomy: a role for serum amylase and C-reactive protein. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 5431-5441.	1.3	10
148	Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms. <i>Annals of Oncology</i> , 2012, 23, 1928.	0.6	9
149	The natural history of a branch-duct intraductal papillary mucinous neoplasm of the pancreas. <i>Surgery</i> , 2014, 155, 578-579.	1.0	9
150	EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). <i>Cancers</i> , 2021, 13, 5014.	1.7	9
151	Alteration in emergency theatre prioritisation does not alter outcome for acute appendicitis: comparative cohort study. <i>World Journal of Emergency Surgery</i> , 2009, 4, 22.	2.1	8
152	Larger hepatic metastases are more frequent with NO colorectal tumours and are associated with poor prognosis: Implications for surveillance. <i>International Journal of Surgery</i> , 2010, 8, 453-457.	1.1	8
153	Pancreatic cystic neoplasms: What is the most cost-effective follow-up strategy?. <i>Endoscopic Ultrasound</i> , 2018, 7, 319.	0.6	8
154	Pancreatic Surgery. <i>Frontiers of Hormone Research</i> , 2015, 44, 139-148.	1.0	7
155	How should incidental NEN of the pancreas and gastrointestinal tract be followed?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 139-144.	2.6	7
156	Endoscopic ultrasound appearance of pancreatic serotonin-staining neuroendocrine neoplasms. <i>Pancreatology</i> , 2018, 18, 792-798.	0.5	7
157	The impact of minimally invasive surgery on hospital readmissions, emergency department visits and functional recovery after distal pancreatectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 5740-5751.	1.3	7
158	MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells. <i>Neuroendocrinology</i> , 2021, 111, 739-751.	1.2	7
159	Impact of care pathway adherence on recovery following distal pancreatectomy within an enhanced recovery program. <i>Hpb</i> , 2021, 23, 1815-1823.	0.1	7
160	Surgical management of pancreatic neuroendocrine neoplasms. <i>Annals of Saudi Medicine</i> , 2014, 34, 1-5.	0.5	7
161	Defining rules for increasingly personalized treatments. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 80-82.	12.5	6
162	Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET). <i>Pancreatology</i> , 2019, 19, 57-63.	0.5	6

#	ARTICLE	IF	CITATIONS
163	Disease-free survival as a measure of overall survival in resected pancreatic endocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2020, 27, 275-283.	1.6	6
164	The Role of Hyponatraemia Before Surgery in Patients With Radical Resected Pancreatic Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492093660.	0.6	5
165	Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma: Legend or Scientific Evidence?. <i>Annals of Surgical Oncology</i> , 2021, 28, 2312-2322.	0.7	5
166	Improved survival after pancreatic re-resection of positive neck margin in pancreatic cancer patients. A systematic review and network meta-analysis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1258-1266.	0.5	5
167	Ampullary Neuroendocrine Neoplasms: Identification of Prognostic Factors in a Multicentric Series of 119 Cases. <i>Endocrine Pathology</i> , 2022, 33, 274-288.	5.2	5
168	Pleomorphic Liposarcoma of the Axilla Metastatic to the Pancreas. <i>Digestive Surgery</i> , 2009, 26, 262-263.	0.6	4
169	Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2017, 266, e108-e109.	2.1	4
170	Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors. <i>Surgery</i> , 2020, 168, 816-824.	1.0	4
171	Single Snapshot Imaging of Optical Properties (SSOP) for Perfusion Assessment during Gastric Conduit Creation for Esophagectomy: An Experimental Study on Pigs. <i>Cancers</i> , 2021, 13, 6079.	1.7	4
172	Survival after active surveillance <i>versus</i> upfront surgery for incidental small pancreatic neuroendocrine tumours. <i>British Journal of Surgery</i> , 2022, 109, 733-738.	0.1	4
173	Pancreatic resections for benign intraductal papillary mucinous neoplasms: Collateral damages from friendly fire. <i>Surgery</i> , 2022, 172, 1202-1209.	1.0	4
174	Duodeno-jejunal or gastro-enteric leakage after pancreatic resection: a caseâ€“control study. <i>Updates in Surgery</i> , 2019, 71, 295-303.	0.9	3
175	Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. <i>European Journal of Surgical Oncology</i> , 2019, 45, 46-51.	0.5	3
176	Indications to total pancreatectomy for positive neck margin after partial pancreatectomy: a review of a slippery ground. <i>Updates in Surgery</i> , 2021, 73, 1219-1229.	0.9	3
177	Clinical and economic validation of grade B postoperative pancreatic fistula subclassification. <i>Surgery</i> , 2022, 171, 846-853.	1.0	3
178	ASO Author Reflections: Circulating Neuroendocrine Gene Transcripts (NETest): A Promising Biomarker for Pancreatic Neuroendocrine Tumours (PanNET). <i>Annals of Surgical Oncology</i> , 2020, 27, 3937-3938.	0.7	2
179	Evaluation of factors predicting loss of benefit provided by laparoscopic distal pancreatectomy compared to open approach. <i>Updates in Surgery</i> , 2021, , 1.	0.9	2
180	Which is the best pancreatic anastomosis?. <i>Minerva Chirurgica</i> , 2019, 74, 241-252.	0.8	2

#	ARTICLE	IF	CITATIONS
181	How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery. <i>Current Oncology Reports</i> , 2022, 24, 227-239.	1.8	2
182	The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 7063-7073.	0.7	2
183	Portal Vein Embolisation for Extended Hepatectomy: Single-Centre Experience. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 413-419.	0.6	1
184	SILS cholecystectomy, early experience of a single institution: pilot study of 21 cases. <i>Updates in Surgery</i> , 2012, 64, 145-148.	0.9	1
185	Comment on "Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine". <i>Surgery</i> , 2014, 155, 582-584.	1.0	1
186	Role of Minimally Invasive Surgery in the Treatment of Pancreatic Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2018, , 141-147.	0.0	1
187	The impact of preoperative anemia on pancreatic resection outcomes. <i>Hpb</i> , 2022, 24, 717-726.	0.1	1
188	Role of chromogranin A-derived fragments after resection of nonfunctioning pancreatic neuroendocrine tumors. <i>Journal of Endocrinological Investigation</i> , 2022, , 1.	1.8	1
189	Questions About Branch-Duct IPMNs With Sendai Negative Criteria. <i>Annals of Surgery</i> , 2014, 259, e42.	2.1	0
190	Guideline for the Management of Pancreatic Neuroendocrine Tumor. , 2017, , 161-172.		0
191	New Surgical Strategies. , 2021, , 113-128.		0
192	Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma?. <i>Digestive and Liver Disease</i> , 2021, 53, 1065-1067.	0.4	0
193	Non Functional Pancreatic Neuroendocrine Tumors. , 2021, , 125-135.		0
194	Surgical Therapy. <i>Updates in Surgery Series</i> , 2013, , 109-116.	0.0	0
195	Functional imaging tests and CT scan: Detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up.. <i>Journal of Clinical Oncology</i> , 2016, 34, 219-219.	0.8	0
196	Therapy for Locoregional Disease: Pancreas. , 2018, , 235-254.		0
197	Pancreatic Neuroendocrine Tumours. , 2018, , 333-343.		0
198	Preoperative risk stratification of postoperative pancreatic fistula: A risk-tree predictive model for pancreatoduodenectomy. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2022, 26, S66-S66.	0.1	0